Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O94923

UPID:
GLCE_HUMAN

ALTERNATIVE NAMES:
Heparan sulfate C5-epimerase; Heparin/heparan sulfate:glucuronic acid C5-epimerase; Heparosan-N-sulfate-glucuronate 5-epimerase

ALTERNATIVE UPACC:
O94923; Q6GUQ2

BACKGROUND:
The enzyme D-glucuronyl C5-epimerase, known for its alternative names such as Heparan sulfate C5-epimerase, is essential in modifying heparan sulfate (HS) and heparin. This modification involves the conversion of D-glucuronic acid to L-iduronic acid, a critical step for the specificity of interactions between these glycosaminoglycans and proteins.

THERAPEUTIC SIGNIFICANCE:
The exploration of D-glucuronyl C5-epimerase's function offers a promising avenue for drug discovery. By elucidating its role in heparan sulfate and heparin modification, researchers can identify novel therapeutic targets for diseases where these molecules play a key role.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.